Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 27, 2022; 14(8): 1678-1686
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1678
Secondary sclerosing cholangitis after critical COVID-19: Three case reports
Juan M Mayorquín-Aguilar, Aldo Lara-Reyes, Luis Alberto Revuelta-Rodríguez, Nayelli C Flores-García, Astrid Ruiz-Margáin, Marco Antonio Jiménez-Ferreira, Ricardo Ulises Macías-Rodríguez
Juan M Mayorquín-Aguilar, Aldo Lara-Reyes, Luis Alberto Revuelta-Rodríguez, Nayelli C Flores-García, Astrid Ruiz-Margáin, Ricardo Ulises Macías-Rodríguez, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico
Marco Antonio Jiménez-Ferreira, Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico
Author contributions: Mayorquín-Aguilar JM, Lara-Reyes A, and Revuelta-Rodríguez LA were the patient´s gastroenterology fellows during their hospitalization; Macías-Rodríguez RU and Flores-García NC were the attending hepatologists; Mayorquin-Aguilar JM, Lara-Reyes A, Macías-Rodríguez RU, and Ruiz-Margain A reviewed the literature and contributed to the manuscript drafting; Jiménez-Ferreira MA was the gastrointestinal pathology fellow in charge of the interpretation and handling of the pathology images.
Informed consent statement: The cases included in this manuscript signed a general informed consent, provided to all patients admitted to our institution with the diagnosis of severe COVID-19. In the manuscript no information regarding ID, name or physical characteristics allowing recognizing the identity of the patients is provided.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ricardo Ulises Macías-Rodríguez, MSc, PhD, Assistant Professor, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Col. Belisario Domínguez Sección XVI, Mexico City 14080, Mexico. ricardomacro@yahoo.com.mx
Received: January 28, 2022
Peer-review started: January 28, 2022
First decision: March 25, 2022
Revised: April 4, 2022
Accepted: August 15, 2022
Article in press: August 15, 2022
Published online: August 27, 2022
Processing time: 210 Days and 7.9 Hours
Core Tip

Core Tip: Coronavirus disease 2019 (COVID-19) multiorganic involvement is well described, including liver disease. In patients with critical COVID-19 requiring invasive mechanical ventilation and management in the intensive care unit, a new entity called “post-COVID-19 cholangiopathy” has been described. It is characterized by persistent cholestasis and chronic liver disease. Therefore, severe COVID-19 infection should be considered a potential risk factor for chronic liver disease probably requiring liver transplantation.